Sign in Subscribe
Cancer research

Improved Lapatinib Sensitivity Prediction in Bladder Cancer Cells

Strategic Insights

— 1 min read

Scientists have developed a new prediction model to determine the effectiveness of lapatinib, a targeted therapy, for treating bladder cancer. The model uses transcriptome-wide profiling and combines it with epidermal growth factor receptor (EGFR) pathway phosphoprotein profiling. This approach has shown excellent predictive performance, with accuracy rates ranging from 86% to 98%. The study's findings have significant implications for personalizing treatment for patients with EGFR-directed targeted therapies.

Key Takeaways:

  • A new prediction model for lapatinib sensitivity in bladder cancer cells has been developed using transcriptome-wide profiling and EGFR pathway phosphoprotein profiling.
  • The model's accuracy rates range from 86% to 98%, indicating its high predictive performance.
  • The study suggests that combining transcriptome-wide profiling with EGFR pathway phosphoprotein profiling data can provide a more accurate prediction model.
  • The model's excellent predictive performance has significant implications for personalizing treatment for patients with EGFR-directed targeted therapies.
  • The study's findings were published in the journal Neoplasia and have the potential to improve treatment outcomes for bladder cancer patients.

Statistics:

  • The study analyzed a panel of 39 human bladder cancer cell lines to empirically determine in vitro sensitivities to lapatinib treatment.
  • The accuracy rates of the prediction models were as follows:

+ 93%-98% for models derived from microarray gene expression data.

+ 54%-61% for models derived from EGFR pathway profiling of 23 selected phosphoproteins.

+ 86% for models derived from a subset of the microarray data for transcripts in the EGFR pathway.

+ 98% for a combination model combining microarray data and phosphoprotein profiling.

  • The study used transcriptome-wide profiling for biomarkers of lapatinib sensitivity in cancer cells, which revealed excellent predictive performance.

Sources:

  • Compare of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia, 2009;11(11):1185-93.
  • Cancer Gene Therapy Week editors from staff and other reports. Copyright 2009, Cancer Gene Therapy Week via NewsRx.com.

Read more